Wedbush Lifts Earnings Estimates for Vigil Neuroscience

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities researchers at Wedbush raised their Q2 2025 earnings estimates for Vigil Neuroscience in a report issued on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.39) per share for the quarter, up from their previous estimate of ($0.43). Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. Wedbush also issued estimates for Vigil Neuroscience’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at ($0.17) EPS.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04.

A number of other equities analysts have also recently issued reports on the stock. William Blair raised shares of Vigil Neuroscience to a “strong-buy” rating in a research report on Thursday, April 24th. HC Wainwright dropped their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, March 14th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Trading Up 4.5%

Shares of Vigil Neuroscience stock opened at $2.53 on Monday. The business has a 50-day moving average price of $1.94 and a two-hundred day moving average price of $2.29. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $6.06. The company has a market cap of $118.08 million, a P/E ratio of -1.23 and a beta of 1.90.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds have recently modified their holdings of the company. abrdn plc increased its stake in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after purchasing an additional 293,461 shares during the last quarter. Blair William & Co. IL bought a new position in Vigil Neuroscience in the 4th quarter valued at $551,000. 683 Capital Management LLC boosted its holdings in Vigil Neuroscience by 14.8% in the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company’s stock valued at $2,380,000 after purchasing an additional 180,420 shares during the period. Marshall Wace LLP lifted its holdings in shares of Vigil Neuroscience by 85.3% during the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company’s stock worth $454,000 after acquiring an additional 122,853 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock worth $624,000 after acquiring an additional 321,300 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.